1. Scrip
  2. >>R&D

Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance

 
• By Joseph Haas

Phase II data presented at CROI aren't sufficient to demonstrate statistical superiority over ViiV's Tivicay, but one analyst predicts that a repeat performance in larger Phase III trials could support a superiority claim.

With Gilead Sciences Inc. calling 2016 one of the company's strongest years for performance in the HIV space, promising Phase II data for its next-generation integrase inhibitor, bictegravir, could position the virology powerhouse to remain the HIV leader even after tenofovir alafenamide (TAF) loses patent protection in 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held Strong

 
• By Alexandra Shimmings

There was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.